{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Stapuldencel-T",
  "nciThesaurus": {
    "casRegistry": "",
    "chebiId": "",
    "chemicalFormula": "",
    "definition": "A dendritic cell (DC)-based cancer vaccine composed of autologous dendritic cells (DCs) activated with a prostate tumor cell lysate containing tumor-associated antigens (TAAs) with potential immunostimulatory and antineoplastic activities. Upon administration, stapuldencel-T  may stimulate an anti-tumoral cytotoxic T-lymphocyte (CTL) response against prostate cancer cells expressing prostate tumor cell-specific antigens, which may result in prostate tumor cell lysis.",
    "fdaUniiCode": "RB8MSD888P",
    "identifier": "C115106",
    "preferredName": "Stapuldencel-T ",
    "semanticType": "Cell",
    "subclassOf": [
      "C2594"
    ],
    "synonyms": [
      "DCVAC/PCa",
      "Prostate Tumor Antigen-activated Autologous Dendritic Cell Vaccine",
      "STAPULDENCEL",
      "Stapuldencel-T "
    ]
  }
}